PSMA as a prostate-specific marker may not be ideal, but the observation of low to negligible counts of PSMA+ve microparticles in healthy volunteers as well as the significant decrease in PSMA+ve microparticles in patients post-prostatectomy reveals its clinical potential as a first generation biomarker for prostate cancer microparticles. Here, FOLH1 is linked to prostate carcinoma.